Compare BridgeBio Pharma Inc (BBIO) vs Shopify Inc. (SHOP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Shopify Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Shopify Inc. trades at $151.51 (market cap $199.66B). The key difference: Shopify Inc. is far larger — about 12× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Shopify Inc. nearer its low. Which is the better fit depends on your goals.
| BBIO | SHOP | |
|---|---|---|
Market Cap | $16.61B | $199.66B |
Sector | Health | Technology |
52-Week High | $90.17 | $179.01 |
52-Week Low | $47.29 | $95.40 |
Enterprise Value | $18.16B | $194.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Shopify (SHOP) trades at $151.57, up 2.8% today, following strong Q2 2026 results that beat earnings and revenue expectations. The stock shows bullish technical momentum with positive moving averages and is trading near key resistance at $154. Fundamentally, revenue growth remains robust at 30%+ with expanding margins, though valuation multiples remain elevated with a P/E of 102.4. Recent news highlights AI-driven commerce growth and strong merchant adoption.
The outlook remains positive with analyst consensus favoring Buy ratings (66%) and a $166 price target. Key opportunities include sustained e-commerce growth and AI integration, while risks include premium valuation sensitivity and competitive pressures. The company's improving cash flow generation and profitability trends support continued upward momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →
